Neonc Technologies Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amir Farrokh Heshmatpour
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8335 Sunset Boulevard Calabasas CA United States of America 90069
- IPO Date
- Mar 26, 2025
- CIK
- 0001979414
- Website
- neonctech.com
- Similar Companies
- Business
- NEONC Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company that develops proprietary, patented platform technologies to transport therapeutics across the blood-brain barrier for treating brain cancers and central nervous system (CNS) diseases; its lead candidates include NEO100, a purified perillyl alcohol formulation in Phase IIa clinical trials for recurrent glioblastoma with FDA Orphan Drug and Fast Track designations, NEO212, a conjugate of temozolomide and perillyl alcohol in Phase I/II trials for primary and secondary brain tumors via oral administration, and the broader NEO platform supporting intranasal and transfemoral delivery methods for enhanced therapeutic efficacy in CNS malignancies such as grade 4 astrocytoma. The company targets oncology biopharmaceutical markets, focusing on glioblastoma and other intracranial tumors, with operations centered in the United States and plans for expansion into the MENA region. Founded in 2008 and headquartered in Calabasas, California, NEONC holds exclusive worldwide rights from USC to an intellectual property portfolio of 135 U.S. and international patents issued and pending, extending protections to 2038. Recent developments include the completion of an $18.5 million financing round in 2024 that valued the company post-money at approximately $220 million and advanced Phase II trials under FDA Fast Track status; a strategic acquisition of advanced AI and 3D bioprinting intellectual property; the appointment of Ishwar Puri to its Board of Directors; initiation of Cohort 3 enrollment in the Phase 1 trial of NEO212; board approval in June 2025 for a $50 million equity investment and MENA expansion via non-binding term sheet with Quazar Investment, including 1.4 million shares at $25 per share and a sub-license agreement with NuroCure; and receipt of the Breakthrough Medical Technology Achievement Award from the California Investment Forum.
The Next Great AI Revolution May Be Drug Delivery
The Next Great AI Revolution May Be Drug Delivery
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Biotech's Next Wave May Already be in Motion
Where Executives Are Doubling Down on Their Companies’ Fortunes
Where Executives Are Doubling Down on Their Companies' Fortunes
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
Neonc Technologies (NASDAQ:NTHI) President Amir Heshmatpour Buys 5,000 Shares
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
Neonc Technologies (NASDAQ:NTHI) Trading Down 0.1% – Should You Sell?
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Sees Significant Growth in Short Interest
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
Neonc Technologies (NASDAQ:NTHI) Trading Up 1.7% – Here’s What Happened
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)